Escitalopram Combination Comparison Study for Adult Patients With Major Depressive Disorder
Phase 3
- Conditions
- Major Depressive Disorder
- Registration Number
- NCT00239954
- Lead Sponsor
- Pharmacology Research Institute
- Brief Summary
The purpose of this study is to evaluate the effectiveness, safety and tolerability of an escitalopram combination treatment compared to single treatments, and to placebo in patients with major depressive disorder.
- Detailed Description
Both active drugs being tested, alone and in combination, in this study are currently available antidepressants. However, the doses used in this study are lower than the standard approved doses.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Patients must meet Diagnostic and Statistical Manual, Fourth Edition (DSM-IV) diagnostic criteria for Major Depressive Disorder
- The patient's current depressive episode must be at least 12 weeks in duration.
Exclusion Criteria
- Women who are pregnant, women who will be breastfeeding during the study, and women of childbearing potential who are not practicing a reliable method of birth control.
- Patients who currently meet DSM-IV criteria for : a. bipolar disorder; b. schizophrenia or any psychotic disorder; c. obsessive-compulsive disorder; d. mental retardation or any pervasive developmental disorder or cognitive disorder.
- Patients who are considered a suicide risk.
- Patients with a history of seizure disorder, or any history of seizure, stroke, significant head injury, or any other condition that predisposes toward risk of seizure.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Montgomery Asberg Depression Rating Scale (MADRS)
- Secondary Outcome Measures
Name Time Method Hamilton Depression Rating Scale (HAMD)
Trial Locations
- Locations (1)
Pharmacology Research Institute
🇺🇸Riverside, California, United States